Efficacy of growth hormone supplementation with ultrashort GnRH antagonist in IVF/ICSI for poor responders; randomized controlled trial.

Autor:	Mohammad EH; Department of Gynecology and Obstetrics, Faculty of Medicine, Al-Azhar University, Egypt., Abou El Serour AG; Department of Gynecology and Obstetrics, Faculty of Medicine, Al-Azhar University, Egypt., Mohamed EAH; Department of Embryology, International Islamic Center for Population Studies & Research, Al Azhar University, Egypt., Abbasy AH; Department of Obstetrics & Gynecology, National Research Center, Egypt., Zaatar M; Department of Obstetrics & Gynecology, National Research Center, Egypt., Rageh KA; Department of Gynecology and Obstetrics, Faculty of Medicine, Al-Azhar University, Egypt., Shafeek MM; Department of Obstetrics & Gynecology, National Research Center, Egypt., Issak ER; Department of Internal Medicine, Nova Clinics, Cairo, Egypt. Electronic address: dr.emad.r.h.issak@gmail.com.
Jazyk:	angličtina
Zdroj:	Taiwanese journal of obstetrics & gynecology [Taiwan J Obstet Gynecol] 2021 Jan; Vol. 60 (1), pp. 51-55.
DOI:	10.1016/j.tjog.2020.10.003
Abstrakt:	Objectives: To compare the ICSI-ET outcomes in poor responders who underwent ovarian stimulation by the ultrashort GnRH antagonist protocol with or without adjuvant GH injection. Material and Methods: This randomized controlled study was conducted at Al-Azhar University from December-2018 to June-2019 upon 156 participants. All patients received the same preparations. After randomization, in the study group, women have received GH 4 IU/day subcutaneous injection from the second day of the cycle stopped one day before ovum pickup. While in the control group, women have received subcutaneous saline in the same dosing as in the study group. After intervention, all procedures were the same in both groups. The main outcome measure was the clinical pregnancy rate. Statistical analysis was based on the intention-to-treat population. Results: Both groups were comparable with regard their baseline characteristics (p-values > 0.05). Ovulation characteristics were comparable (p-values > 0.05). The level of E2 is significantly (p-value = 0.003) higher in the GH group. The oocyte retrieved number was significantly (p-value < 0.001) higher in the GH group 4.94 ± 1.77 than in the control group 3.74 ± 1.82. The mean number of MII oocytes was significantly (p-value < 0.001) higher in the GH group 3.3 ± 1.36 than in the control group 2.29 ± 1.24. Fertilization characteristics, implantation rate, pregnancy rate were comparable (p-values > 0.05). Conclusion: Despite the fact that this study showed no significant increase in the clinical and chemical pregnancy rates by the addition of GH to the ultrashort antagonist protocol in poor responders, the number of retrieved oocytes was significantly higher in the GH group. Clinical Trial Registration: ClinicalTrials.gov Identifier: NCT03759301. Competing Interests: Declaration of competing interest All authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported. (Copyright © 2021. Published by Elsevier B.V.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu